Skip to main navigation

Hablamos Español


FDA Panel Recommends New Depression Treatment/THE NEW YORK TIMES FEB12/2019

ketamine nasal spray is in the process of being approved by the FDA a step forward in the direction of IV ketamine therapy, which many anesthesiologist, psychiatrist, and key witnesses have been trying to push forward . Developed by Johnson and Johnson Esketamine, was  presented to the FDA by consumer witnesses and  17 top psychiatrists, and it  was unanimously decided the benefits far outweighed any risks of the drug.  it was being presented as  a treatment for depression, especially suicidal ideation.  It does have its other uses for example with OCD, anxiety, bipolar depression, and acute and chronic pain.

Read More